GlassScriptPhysician profile
Evelyn Keaton
NPI 1306942529
$3,814.44
in general payments reported to CMS, 2019-2025
24 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $821 · 2022: $622 · 2023: $1,008 · 2024: $924 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $56.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.51 |
| Education | $56.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $906.70 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $832.14 | 2021-2024 | Airsupra, Fasenra, Breztri |
| Genzyme Corporation | $378.71 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.85 | 2021-2024 | Spiriva Respimat |
| Alk-Abello, INC | $217.13 | 2021-2024 | Grastek, Odactra |
| Regeneron Healthcare Solutions, INC. | $200.23 | 2021-2025 | Dupixent |
| Optinose US, INC. | $160.26 | 2022-2025 | |
| Kaleo, INC. | $151.75 | 2022-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $102.97 | 2023-2024 | Cuvitru |
| Amgen INC. | $81.38 | 2023-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $65.41 | 2024-2025 | |
| Covis Pharma Gmbh | $59.65 | 2021-2022 | |
| Smith+Nephew, INC. | $58.54 | 2025 | Tula |
| Sanofi-Aventis U.S. LLC | $56.99 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $55.53 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $44.24 | 2021-2024 | Yupelri |
| Pharming Healthcare, INC. | $32.81 | 2021-2024 | Ruconest |
| Leo Pharma INC. | $25.65 | 2023 | Adbry |
| Abbvie INC. | $24.88 | 2022 | |
| Pfizer INC. | $24.30 | 2024 | |
| Octapharma USA, INC. | $19.63 | 2024 | Cutaquig |
| Boston Scientific Corporation | $17.61 | 2024 | Wavewriter Alpha Prime 16 |
| Genentech USA, INC. | $17.00 | 2021 | |
| Philips North America LLC | $14.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evelyn Keaton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.